Earlier Discharge or Stepdown
Fast antimicrobial susceptibility test (AST) results from the Accelerate Pheno® system can help clinicians reduce length of stay (LOS) for patients with bacteremia — a leading cause of sepsis — by 2 days or more.
And during a crisis like the COVID-19 pandemic, the sooner patients are discharged or stepped down, the sooner their beds are free for other patients.
For example, fast results from the Accelerate Pheno® system have helped the University of Arkansas for Medical Sciences reduce inpatient LOS for bacteremic inpatients by 2.4 days. See below how these LOS reductions can help hospitals manage beds more efficiently for the patients who need them most.
Length of Stay Reductions
Fast Results for Clinical Optimization
Clinical microbiology laboratories at hospitals across the United States are using the Accelerate Pheno system to cut the wait time for antimicrobial susceptibility test (AST) results by approximately 40 hours.
Antimicrobial stewardship teams are using these expedited phenotypic AST results to support faster and better decision-making around antibiotic therapy recommendations.
Earlier clinical optimization with faster microbiology results from the Accelerate Pheno system provides multiple benefits in addition to LOS reductions:
- ID in ~2 hours, AST in ~7 hours
- Expedited results reporting4
- Timely therapy optimization2,5,6 (escalation and de-escalation)
- Reduced antibiotic days on therapy1,2,3
1.Sheth S, et al. Impact of Rapid Identification (ID) and Antimicrobial Susceptibility Testing (AST) on Antibiotic Therapy and Outcomes for Patients with Bacteraemia/Candidaemia. Poster presented at: ECCMID; April 2019, Amsterdam, Netherlands.
2.Walsh T. Impact of Accelerate Pheno™ System on Management of Gram Negative Bacteremia at an Academic Medical Center. Poster presented at: SCACM WV; October 2019, Morgantown, WV.
3.Pearson C, et al. Impact of Accelerate Pheno™ Rapid Blood Culture Detection System with Real Time Notification versus Standard Antibiotic Stewardship on Clinical Outcomes in Bacteremic Patients. Oral presentation at: IDWeek™; October 2019, Washington, D.C.
4.Charnot-Katsikas A, et al. Use of the Accelerate Pheno™ System for Identification and Antimicrobial Susceptibility Testing of Pathogens in Positive Blood Cultures and Impact on Time to Results and Workflow. J Clin Microbiol 2018; 56:e01166-17.
5.Banerjee R, et al. Randomized clinical trial evaluating clinical impact of RAPid IDentification and antimicrobial Susceptibility testing for Gram-Negative bacteremia (RAPIDS-GN). Poster presented at: IDWeek™; October 2019, Washington, D.C.
6.Schneider JC, et al. Susceptibility Provision Enhances Effective De-Escalation (SPEED). Utilizing Rapid Phenotypic Susceptibility Testing in Gram-Negative Bloodstream Infections and its Potential Clinical Impact. J Antimicrob Chemother 2019; 74 Suppl 1: i16–i23.